Dr. Courtney Jordan Baechler

And now, Oh, what did they just get an FDA approval for cardiac prevention? So it is so interconnected that basically all the trials that we do on the clinical side. Now we look at, the SLP ones that we use in heart failure have diabetes implications in terms of improving because it's just, it's such an interconnected process. And in fact, from an epi perspective, the next sort of biggest proposed

And now, Oh, what did they just get an FDA approval for cardiac prevention? So it is so interconnected that basically all the trials that we do on the clinical side. Now we look at, the SLP ones that we use in heart failure have diabetes implications in terms of improving because it's just, it's such an interconnected process. And in fact, from an epi perspective, the next sort of biggest proposed

issue that we're going to have as a country is diabetes actually overtaking cardiovascular disease, which again, isn't surprising, like we just said, because in this case, it usually comes first, and then cardiovascular disease comes second with what we're dealing with now, with our culture of obesity and poor nutrition and poor exercise and poor sleep and high stress.

issue that we're going to have as a country is diabetes actually overtaking cardiovascular disease, which again, isn't surprising, like we just said, because in this case, it usually comes first, and then cardiovascular disease comes second with what we're dealing with now, with our culture of obesity and poor nutrition and poor exercise and poor sleep and high stress.

And now I can't help, but yeah, I can't help, but just add one more thing for our, for your listeners too, is that the number one thing I hear from people when we want to start a statin drug, which, you know, is the number one drug that we prescribe in this country, not as cardiologists, but as anybody is, oh, I've heard that they cause diabetes, statin drugs in trials and

And now I can't help, but yeah, I can't help, but just add one more thing for our, for your listeners too, is that the number one thing I hear from people when we want to start a statin drug, which, you know, is the number one drug that we prescribe in this country, not as cardiologists, but as anybody is, oh, I've heard that they cause diabetes, statin drugs in trials and

they showed people who are on statins got diabetes six months earlier. And for Gemini and anybody who's an epidemiologist, that is what we call true, true and unrelated because people are usually walking around with, diabetes for quite some time before we actually diagnose it.

they showed people who are on statins got diabetes six months earlier. And for Gemini and anybody who's an epidemiologist, that is what we call true, true and unrelated because people are usually walking around with, diabetes for quite some time before we actually diagnose it.

And so it's totally not causally related to these drugs and speaks more to what we are saying in that these conditions, diabetes and cardiovascular disease for the individual that is living with them coincide often together. And so it really takes a more holistic look at how we prevent it, treat it effectively and prevent deaths.

And so it's totally not causally related to these drugs and speaks more to what we are saying in that these conditions, diabetes and cardiovascular disease for the individual that is living with them coincide often together. And so it really takes a more holistic look at how we prevent it, treat it effectively and prevent deaths.

Yeah. The only thing I would add to that is, can we, excuse me, be patient and wait? Because again, there are a lot of examples that have shown that if you respond to what community is actually asking for, we can get to this place. But so far, we've been impatient and wanting to our needs, our clinical needs met first and just met resistance.

Yeah. The only thing I would add to that is, can we, excuse me, be patient and wait? Because again, there are a lot of examples that have shown that if you respond to what community is actually asking for, we can get to this place. But so far, we've been impatient and wanting to our needs, our clinical needs met first and just met resistance.

So I think this is really, I think it's a critical piece that we give this time and are open to some of, quote, the softer metrics that might actually be more important than some of, quote, the hard metrics that we've done.

So I think this is really, I think it's a critical piece that we give this time and are open to some of, quote, the softer metrics that might actually be more important than some of, quote, the hard metrics that we've done.

I think your point is a good one, Erin. And we certainly did our very best in making this plan to be engaging with community. Obviously, the ones that we engage with were people who wanted to engage to what you're saying. But the Department of Health and the leadership team that helped create this had lots of

I think your point is a good one, Erin. And we certainly did our very best in making this plan to be engaging with community. Obviously, the ones that we engage with were people who wanted to engage to what you're saying. But the Department of Health and the leadership team that helped create this had lots of

various connections that way that we tried to use as much as possible to engage with people and different sectors that historically have not been involved. And I think part of our thinking that way is that we sort of just continue to build that tree with broader roots as we change who is involved and look at different ways, easier ways for people to engage in terms of

various connections that way that we tried to use as much as possible to engage with people and different sectors that historically have not been involved. And I think part of our thinking that way is that we sort of just continue to build that tree with broader roots as we change who is involved and look at different ways, easier ways for people to engage in terms of

how we access virtually in person, you know, all the different things that that's not how it's always been in the past. So I think like everything else, the proof will be in the pudding, right? And the final product in the sense of, I'm sure there are some people who are kind of cautiously watching from afar to see, well, let me see how that works with that group. And if that goes well, then

how we access virtually in person, you know, all the different things that that's not how it's always been in the past. So I think like everything else, the proof will be in the pudding, right? And the final product in the sense of, I'm sure there are some people who are kind of cautiously watching from afar to see, well, let me see how that works with that group. And if that goes well, then